228 - Incidence, Severity, Day 100 Treatment Efficacy and Therapy Toxicity of Cytomegalovirus (CMV) Infections with Early Pre-Emptive Therapy in Adult Cord Blood (CB) Transplant Recipients

Abstract

Abstract Introduction: Unrelated donor CB transplantation (CBT) is effective therapy for patients (pts) with high-risk hematologic malignancies without suitable adult donors. CBT, however, can be complicated by CMV infection in seropositive recipients with viremia rates as high as 100%. Moreover, CMV infection is associated with increased transplant-related mortality (TRM) in some reports. Therefore, our center is investigating: 1) the efficacy of pre-transplant ganciclovir (GAN) prophylaxis, 2) the efficacy of early pre-emptive therapy based on frequent serial qPCR monitoring, & 3) anti-viral therapy toxicities. The aim of this strategy is to rapidly eradicate viremia & thereby prevent disease without prohibitive toxicity. Methods: Eligible pts were adult CMV seropositive 1st allograft CB recipients transplanted 3/2013-2/2016. Pts received Cy 50/Flu 150/Thio 5-10/TBI 400 cGy myeloablative conditioning + CSA/MMF (no ATG). GAN prophylaxis (5 mg/kg IV daily) was given days -7 to -2. Viremia was evaluated by qPCR (lower detection limit 137 copies/ml) twice weekly from day +14 or earlier if indicated. Treatment for viremia was usually initiated at 1st or 2nd qPCR positivity. Foscarnet (FOS), GAN or valganciclovir (VALGAN) dosing (maintenance vs induction) was selected based on viremia level & assessment of severe infection vs toxicity risk. CMV disease was treated with induction dosing. CMV response was defined as 3 consecutive negative qPCR & no evidence of disease. Results: 42 CBT recipients [median 51 years (range 23-66), 33 acute leukemias, 6 MDS/MPD, 3 lymphomas] received double unit grafts [median donor-recipient HLA-allele match 5/8 (range 2-7/8) & infused CD34+ cell dose 1.3 (range 0.2-3.2) x 105/kg/unit]. 98% of pts engrafted (1 graft failure unrelated to CMV) & 86% (26 gr. II, 7 gr. III, 3 gr. IV) had gr. II-IV aGVHD by day 100 (median onset 29 days, range 19-35). Of the 42 pts, 35 reactivated CMV in the first 100 days [median viremia onset 33 days (range 5-74) & median viral load at 1st detection Conclusion: CMV infection is very frequent in adult seropositive CBT recipients & pre-CBT GAN is not effective prophylaxis. Early intensive monitoring permits early pre-emptive therapy which is effective in most pts. While maintenance dosing is effective in some, the development of lethal CMV pneumonia in 2 maintenance pts suggests dose escalation may be appropriate if rapid viremia eradication is not achieved. However, FOS/GAN/VALGAN toxicities are also significant. Ultimately, the optimal drug dosing to enhance efficacy but mitigate toxicity, how to predict pts at greatest risk of disease, appropriate therapy duration, & how to predict recurrence risk are not known. Improved CMV prophylaxis & therapy for allograft recipients including CBT pts are needed. Download : Download high-res image (281KB) Download : Download full-size image Download : Download high-res image (147KB) Download : Download full-size image Disclosures No relevant conflicts of interest to declare.